Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ArriVent BioPharma (AVBP) Change in Accured Expenses (2023 - 2026)

ArriVent BioPharma has reported Change in Accured Expenses over the past 4 years, most recently at -$3.8 million for Q1 2026.

  • Quarterly results put Change in Accured Expenses at -$3.8 million for Q1 2026, up 21.54% from a year ago — trailing twelve months through Mar 2026 was $7.7 million (up 213.61% YoY), and the annual figure for FY2025 was $6.7 million, up 4.55%.
  • Change in Accured Expenses reached -$3.8 million in Q1 2026 per AVBP's latest filing, down from $4.4 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $7.0 million in Q2 2025 and bottomed at -$4.9 million in Q1 2025.
  • Median Change in Accured Expenses over the past 4 years was $1.6 million (2023), compared with a mean of $828615.4.
  • The largest annual shift saw Change in Accured Expenses soared 282.23% in 2024 before it plummeted 406.65% in 2025.
  • Over 4 years, Change in Accured Expenses stood at $1.6 million in 2023, then surged by 81.71% to $3.0 million in 2024, then surged by 49.04% to $4.4 million in 2025, then tumbled by 186.45% to -$3.8 million in 2026.
  • Business Quant data shows Change in Accured Expenses for AVBP at -$3.8 million in Q1 2026, $4.4 million in Q4 2025, and $91000.0 in Q3 2025.